Literature DB >> 24930471

A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia.

A Nutman1, R Glick, E Temkin, M Hoshen, R Edgar, T Braun, Y Carmeli.   

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) is an increasingly common nosocomial pathogen. We sought to identify clinical and microbiological predictors of 14-day mortality among patients with CRAB bacteraemia. This case-control study included all adult patients in one Israeli hospital with CRAB on blood culture between July 2008 and June 2011. Cases were defined as patients who died within 14 days of bacteraemia onset and controls as patients who survived over 14 days. Sequence-typing of the blaOXA-51-like gene and REP-PCR identified CRAB clone groups. Logistic regression was performed to analyze predictors of 14-day all-cause mortality. To correct for differences in treatment onset, Cox regression was used to examine the effect of receiving an active antibiotic. Eighty-three cases and 89 controls were included. Six major CRAB clone groups were identified, with 14-day mortality ranging from 17 to 66%. Independent predictors of 14-day mortality were severity of illness (OR = 1.38 for each 1-point increase in Sequential Organ Failure Assessment (SOFA) score; 95% CI, 1.21, 1.56), independence in activities of daily living (ADL) on admission (OR = 3.40; 95% CI, 1.20, 9.67, for fully dependent vs. independent), surgery before bacteraemia (OR = 0.25; 95% CI, 0.11, 0.59) and clone group (OR = 7.76; 95% CI, 2.52, 23.85, for the most virulent group vs. the reference group). In the multivariate Cox model using a propensity score to adjust for SOFA, clone, ADL and surgery, active antibiotic treatment was protective (HR = 0.30; 95% CI, 0.15, 0.60). Differences in virulence between CRAB clones may partly explain heterogeneous results in previous studies of mortality following CRAB infection.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  bacteraemia; carbapenem-resistant Acinetobacter baumannii; molecular epidemiology; mortality

Mesh:

Substances:

Year:  2014        PMID: 24930471     DOI: 10.1111/1469-0691.12716

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  25 in total

1.  Morbidity and mortality risk factors in emergency department patients with Acinetobacter baumannii bacteremia.

Authors:  Rui-Xue Sun; Priscilla Song; Joseph Walline; He Wang; Ying-Chun Xu; Hua-Dong Zhu; Xue-Zhong Yu; Jun Xu
Journal:  World J Emerg Med       Date:  2020

Review 2.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Risk factors and clinical outcomes for intensive care unit patients with mul-tidrug-resistant Acinetobacter spp. bacteremia.

Authors:  Malbaša Đekić; T Dugandžija; G Dragovac; D Medić; M Paut Kusturica
Journal:  Hippokratia       Date:  2020 Jan-Mar       Impact factor: 0.471

4.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

5.  Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Marco Falcone; Giusy Tiseo; Alessandro Leonildi; Leonardo Della Sala; Alessandra Vecchione; Simona Barnini; Alessio Farcomeni; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

6.  Comparison of Cefepime-Cefpirome and Carbapenem Therapy for Acinetobacter Bloodstream Infection in a Multicenter Study.

Authors:  Yea-Yuan Chang; Ya-Sung Yang; Shang-Liang Wu; Yung-Chih Wang; Te-Li Chen; Yi-Tzu Lee
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 7.  Systematic review and meta-analysis of the proportion and associated mortality of polymicrobial (vs monomicrobial) pulmonary and bloodstream infections by Acinetobacter baumannii complex.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis
Journal:  Infection       Date:  2021-07-14       Impact factor: 3.553

Review 8.  A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii.

Authors:  Kimberly C Claeys; Anna D Fiorvento; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2014-12-05

Review 9.  Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Authors:  Eric Wenzler; Debra A Goff; Romney Humphries; Ellie J C Goldstein
Journal:  Infect Dis Ther       Date:  2017-03-04

10.  Risk Factors and Clinical Outcomes for Patients With Acinetobacter baumannii Bacteremia.

Authors:  Zhenyang Gu; Yuliang Han; Taojiang Meng; Shasha Zhao; Xiaoli Zhao; Chunji Gao; Wenrong Huang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.